Reviewed & approved by Dr. Nova Reyes · Last checked 2026-10-15. ← Back to Evidence Library

BPC-157: what the evidence says

At a glance

What it is: a lab-made peptide (a short chain of 15 amino acids, the building blocks of proteins). It is based on a piece of a protein found in stomach juice. It is sold online as a "research chemical" for healing injuries. ^R1

What the evidence says: promising in animals, essentially untested in people. ^{R2, R3}

Biggest risks: not knowing what's really in the vial. There is also a theoretical cancer concern. It makes new blood vessels grow, which helps healing but could in theory also feed a tumor. This hasn't been studied in people. ^{R4, R5, R6}

	Rating
Human Human evidence	Very limited: 3 small clinic reports with no comparison group, no trials ^R2
Animal Animal evidence	Moderate, mostly one lab (Sikirić group) ^R3
Regulatory	Not FDA-approved · WADA-banned ^{R7, R8}
Established human dose	Unknown Unknown

Evidence verdict: Human: Very limited · Animal: Moderate, mostly one lab (Sikirić group) Card verdict: Very limited (3 small uncontrolled clinic reports) · Controlled human trials for tendon, muscle, or gut healing: No human data Card note: Varies by use, see page

This page reports what studies used. It is not dosing advice.

Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source

What is it?

BPC-157 is a short chain of 15 amino acids. It is described as a piece of a protein found in human stomach juice (gastric juice). Since the 1990s it has been tested mostly in rats. Researchers looked at healing of tendons, muscle, the gut and blood vessels. ^R1

Does it work?

Animal In animals: many rat studies report that cut tendons and muscles healed faster and stronger. Most of these studies come from one research group in Croatia, at the University of Zagreb. ^R3

Human In people: we don't know yet. Only three small reports exist. All come from private clinics, and none had a comparison group. They describe less pain. But studies like these can't tell a real effect apart from placebo (feeling better because you expect to), from healing on its own, or from pain that was at its worst simply easing back toward normal. ^R2

Is it safe?

Human The few people studied (2 to 16 per report) had no reported side effects. That is far too few people to rule out rare harms or harms that show up later. ^R2
Animal Formal safety testing in four animal species found no serious toxicity (serious harm, like organ damage). ^R5
Caution Theoretical concern: BPC-157 makes new blood vessels grow, which helps healing but could in theory also feed a tumor. No one has tested whether this matters in people. ^{R4, R6}
Caution The FDA flagged possible immune reactions and problems with impurities. It says it doesn't have enough information to know whether BPC-157 harms people. ^R7

What we don't know

Unknown A safe or effective human dose
Unknown Dose-finding trials (studies that test which amount is safe and works)
Unknown Controlled evidence that it works in people
Unknown Long-term safety (including cancer and pregnancy)
Unknown How much of it reaches the body in people when taken by mouth or injected under the skin ^{R2, R9}

Is it legal?

It is not FDA-approved. In July 2026, an FDA advisory committee recommended letting compounding pharmacies make it for ulcerative colitis, against FDA staff advice. (Compounding pharmacies prepare custom medicines for individual patients, with a prescription.) That vote is only advice. It doesn't change the legal status yet. It is banned for athletes at all times under WADA (World Anti-Doping Agency) rules. ^{R7, R8}

What's in the vial?

With a gray-market vial (one sold outside regulated channels), the contents are the biggest unknown. It could hold the wrong compound or the wrong amount. It could also contain impurities, bacterial toxins or heavy metals. We test retail vials blind under the Open Peptide Standard. See results at /tests/. A passing test covers one batch, tested on one date. It does not mean the compound itself is safe. ^{R7, R10}

What do users report?

Self-report, not evidence.

Unknown TBD. We'll only list this once we can cite a public source.

Study details

^R2 Human Human studies: full table

As of Oct 2026, PubMed-indexed human data are three uncontrolled reports from private clinics, all with the same first author (Lee E). There are no randomized trials. Independent reviews call the human data "extremely limited" (McGuire 2025, PMID 40789979) and found no human safety data meeting their criteria (Vasireddi 2025, PMID 40756949).

Study	People	Route	Dose used	Follow-up	Reported	Limitations	Citation
Lee & Padgett 2021, knee pain	16 (12 BPC-157 alone, 4 with TB4)	Into the knee joint	Caution Not in abstract UNVERIFIED	Retrospective; mostly 6–12 mo after injection	11/12 BPC-only improved (per abstract)	No control; phone recall; no validated measures. Caution A later review summarized the same study as 7/12 with relief for more than 6 mo	PMID 34324435
Lee, Walker & Ayadi 2024, interstitial cystitis	12 women	Injected into the bladder wall	10 mg total, once	Not in abstract	10/12 complete resolution; no adverse events reported	No control; single clinic; self-rated; compounded product	PMID 39325560
Lee & Burgess 2025, IV safety	2 adults	IV, 1 hr	10 mg day 1, 20 mg day 2	3 days	No lab changes; no side effects	n=2, three days long	PMID 40131143

UNVERIFIED Older papers say a BPC-157 formulation (PL 14736 / PLD-116, Pliva) was in clinical trials for inflammatory bowel disease (PMID 14554208). We found no published results.

^R3 Animal Animal and lab studies: dose table

These are doses researchers used, not recommendations. Animal doses don't convert simply to people. A 2025 systematic review included 35 preclinical studies and 1 clinical study (PMID 40756949). Much of the work comes from one group at the University of Zagreb, Croatia (e.g., Sikiric P, Seiwerth S), and independent replication is thin. That group's own review summarizes its BPC-157 research program (Sikiric 2020, PMID 31158953; authors at the University of Zagreb Medical Faculty). The tendon and muscle studies in this table (PMIDs 14554208, 16609979, 20388964) are co-authored by Sikiric and Seiwerth.

Species	Model	Route	Doses	Duration	Outcome	Citation
Rat	Cut Achilles tendon	i.p. daily	10 µg, 10 ng, 10 pg /kg	≤14 d	Better strength, function, repair	PMID 14554208
Rat	Cut quadriceps	i.p. daily	10 µg, 10 ng, 10 pg /kg	≤72 d	Improved healing and function	PMID 16609979
Rat	Crushed/cut muscle and tendon	Unknown Not in abstract	Unknown	Unknown	Angiogenesis modulated, VEGF up	PMID 20388964
Rat, chick embryo, human cells	Hind-limb ischemia	Unknown Not in abstract	Unknown	Unknown	Faster blood-flow recovery, VEGFR2 activation	PMID 27847966
Rat cells	Tendon fibroblasts	In vitro	Dose-dependent	n/a	Better survival and migration	PMID 21030672
Rat, dog	Pharmacokinetics ^R9	IV, IM	3 ascending doses	Single and repeated	Half-life under 30 min; IM bioavailability 14–19% (rat), 45–51% (dog)	PMID 36588717
Mouse, rat, rabbit, dog	Toxicology ^R5	Unknown Not in abstract	Up to 2 mg/kg (dog)	Repeated + 2-wk recovery	No serious toxicity; reversible creatinine drop at 2 mg/kg; mild injection-site irritation	PMID 32334036

^R4–R6 Safety evidence and theoretical concerns

^R4 Angiogenesis: BPC-157 increased vessel growth and activated VEGFR2-Akt-eNOS signaling in chick embryo, rat and cell models (Hsieh 2017, PMID 27847966).
^R5 Animal toxicology: no serious toxicity in mice, rats, rabbits or dogs; reversible creatinine decrease at the highest dog dose (see animal table); mild local irritation; no genetic or embryo-fetal toxicity (Xu 2020, PMID 32334036).
^R6 Cancer concern: a 2026 review lists "pathological angiogenesis" and "carcinogenesis" among potential risks of unregulated peptides including BPC-157 (Moiz 2026, PMID 42757290). This is mechanistic only; we know of no human data either way.

^R7–R8 Regulatory status (as of Oct 15, 2026)

^R7 FDA: not approved. Listed among substances previously in Category 2 whose nominations were withdrawn. FDA states BPC-157 "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization… the agency lacks sufficient information to know whether the drug would cause harm when administered to humans." (FDA page)
Caution UNVERIFIED On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed BPC-157 for ulcerative colitis; FDA staff proposed that it NOT be added to the 503A bulks list (FDA briefing). STAT, July 24, 2026 reports the committee voted 8–6 in favor. FDA has not posted minutes on its meeting page (checked Oct 15, 2026), so the count is from news coverage only. The April 22, 2026 Category 2 removal date comes from law-firm summaries (the FDA page is marked content current as of Apr 22, 2026).
^R8 WADA: named under S0 (Non-approved substances) on the 2026 Prohibited List, prohibited at all times (WADA). Doping labs have validated detection methods (PMID 42328738). Unknown Re-check against the 2027 list.

^{R1, R9, R10} Background, pharmacokinetics, product quality

^R1 Sequence GEPPPGKPADDAGLV; described as a gastric-juice protein fragment (Staresinic 2003, PMID 14554208; Chang 2011, PMID 21030672).
^R9 Pharmacokinetics measured only in rats and dogs (He 2022, PMID 36588717).
^R10 Reviewers name contamination, impurities and inaccurate dosing as key risks of unregulated use (Vasireddi 2025, PMID 40756949; Moiz 2026, PMID 42757290). Open Peptide Standard panel: identity (mass spec), purity (HPLC), content, endotoxin, heavy metals, and sterility where offered; ISO/IEC 17025 lab; blind samples; results tied to a batch, and they expire. Unknown BPC-157 results pending the first batch.

Full reference list (all verified on PubMed, Oct 15, 2026)

Staresinic M, et al. J Orthop Res. 2003;21(6):976-83. doi:10.1016/S0736-0266(03)00110-4. PMID 14554208
Staresinic M, et al. J Orthop Res. 2006;24(5):1109-17. doi:10.1002/jor.20089. PMID 16609979
Sikiric P, et al. Gut Liver. 2020;14(2):153-167. doi:10.5009/gnl18490. PMID 31158953
Brcic L, et al. J Physiol Pharmacol. 2009;60 Suppl 7:191-6. PMID 20388964
Chang CH, et al. J Appl Physiol. 2011;110(3):774-80. doi:10.1152/japplphysiol.00945.2010. PMID 21030672
Hsieh MJ, et al. J Mol Med. 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y. PMID 27847966
Xu C, et al. Regul Toxicol Pharmacol. 2020;114:104665. doi:10.1016/j.yrtph.2020.104665. PMID 32334036
Lee E, Padgett B. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435
He L, et al. Front Pharmacol. 2022;13:1026182. doi:10.3389/fphar.2022.1026182. PMID 36588717
Lee E, Walker C, Ayadi B. Altern Ther Health Med. 2024;30(10):12-17. PMID 39325560
Lee E, Burgess K. Altern Ther Health Med. 2025;31(5):20-24. PMID 40131143
Vasireddi N, et al. HSS J. 2025;21(4):485-495. doi:10.1177/15563316251355551. PMID 40756949
McGuire FP, et al. Curr Rev Musculoskelet Med. 2025;18(12):611-619. doi:10.1007/s12178-025-09990-7. PMID 40789979
Moiz A, et al. Mo Med. 2026;123(4):337-343. PMID 42757290
Mazzarino M, et al. Analyst. 2026;151(15):4398-4413. doi:10.1039/d6an00455e. PMID 42328738

Disclaimer

This page is for education and harm reduction. It is not medical advice and not a recommendation to use BPC-157. Its safety in humans is not established. Please talk to a clinician you trust, especially if you have or have had cancer, are pregnant or trying to conceive, are a tested athlete, or take other medicines. Seek care right away for a serious reaction, and report it to FDA MedWatch (https://www.fda.gov/safety/medwatch).